Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Pluvicto 2026 Cleveland is a federal award for 250-Network Contract Office 10 (36C250) held by Novartis Pharmaceuticals Corp. Estimated value $502K ($502K obligated). Current period of performance ends Dec 31, 2026. Last award drew 1 bidder. Place of performance: EAST HANOVER NJ.
Pluvicto 2026 cleveland. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Dec 31, 2026 (75 days remaining). Agencies typically plan 12–18 months ahead — at 2.5 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 36C25026F0204? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C25026F0204?
36C25026F0204 (Pluvicto 2026 cleveland) is a 250-Network Contract Office 10 (36C250) award with a potential value of $502K, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C250-26-F-0204?
36C250-26-F-0204 is the dashed form of PIID 36C25026F0204 (Pluvicto 2026 cleveland), held by Novartis Pharmaceuticals Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C25026F0204?
250-Network Contract Office 10 (36C250) awarded 36C25026F0204 to Novartis Pharmaceuticals Corp (potential $502K).
Who is the incumbent on 36C25026F0204?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.
When does Novartis Pharmaceuticals Corp’s 36C25026F0204 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C25026F0204? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.